Results of treatment with an intensive induction regimen using idarubicin in combination with cytarabine and etoposide in children with acute myeloblastic leukemia

Leukemia Research

Volumn 20, Issue 11-12, 1996, Pages 973-981

  Sackmann Muriel, Federico ^a   Zubizarreta, Pedro ^a   Felice, María Sara ^a   Chantada, Guillermo ^a   Cygler, Ana María ^a   Gallego, Marta ^a   Rossi, Jorge ^a  

^a HOSPITAL DE PEDIATRÍA PROF DR JUAN P GARRAHAN   (Argentina)

Author keywords

Acute myeloblastic leukemia; Ara C; Children; Etopside; Idarubicin; Prognostic groups

Indexed keywords

CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; IDARUBICIN; MERCAPTOPURINE; PREDNISONE; RETINOIC ACID; TIOGUANINE; VINCRISTINE;

ACUTE MYELOBLASTIC LEUKEMIA; ADOLESCENT; ALOPECIA; ARTICLE; BONE MARROW SUPPRESSION; CANCER MORTALITY; CARDIOTOXICITY; CENTRAL NERVOUS SYSTEM; CHILD; CHILDHOOD LEUKEMIA; CLINICAL TRIAL; FEMALE; FOLLOW UP; GASTROINTESTINAL TOXICITY; HIGH RISK POPULATION; HUMAN; HUMAN CELL; INFANT; INFECTION; INTRATHECAL DRUG ADMINISTRATION; LEUKEMIA REMISSION; LEUKOPENIA; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOCYTOPENIA;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; CYTARABINE; ETOPOSIDE; FEMALE; HUMANS; IDARUBICIN; INFANT; LEUKEMIA, MYELOID; LIFE TABLES; MALE; PROSPECTIVE STUDIES; REMISSION INDUCTION; TREATMENT OUTCOME;

EID: 0030293118     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0145-2126(96)00071-9     Document Type: Article

References (39)

1. 1. Hurwitz C. A., Mounce K. G. & Grier H. E. (1995) Treatment of patients with acute myelogenous leukemia: Review of clinical trials of the past decade. J. Pediatr. Hematol. Oncol. 17, 185.
2. 2. Arcamone F., Bernardi L., Giardini P., Patelli B., Marco A., Casazza A. M., Fratesi G. & Reggiani P. (1976) Synthesis and antitumor activity of 4-demethoxydaunorubicin, 4-demethoxy-7-diepidaunorubicin and their anomers. Cancer Treat. Rep. 60, 829.
3. 3. Casazza A. M., Pratesi G., Giuliani F. & Di Marco A. (1980) Antileukemic activity of 4-demethoxydaunorubicin in mice. Tumori 66, 549.
4. 4. Casazza A. M. (1979) Experimental evaluation of anthracycline analogs. Cancer Treat. Rep. 63, 835.
5. 5. Ganzina F., Pacciarini M. A. & De Pietro N. (1986) Idarubicin (4-demethoxydaunorubicin): A preliminary review of pre-clinical and clinical studies. Invest. New Drugs 4, 85.
6. 6. Berman E., Heller G., Santorsa J., McKenzie S., Gee T., Kempin S., Gulati S., Andreeff M., Kolitz J., Gabrilove J., Reich L., Mayer K., Keefe D., Trainor K., Scluger A., Penenberg D., Raymond V., O'Reilly R., Jhanward S., Young C. & Clarkson B. (1991) Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia. Blood 77, 1666.
7. 7. Wiernik P. H., Banks P. L. C., Case D. C., Arlin Z. A., Periman P. O., Todd M. B., Ritch P. S., Enck R. E. & Weitberg A. B. (1992) Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia. Blood 79, 313.
8. 8. Vogler W. R., Velez-García E., Omura G. & Raney M. (1989) A phase-three trial comparing daunorubicin or idarubicin combined with cytosine arabinoside in acute myelogenous leukemia. Semin. Oncol. 16, 2, 21.
9. 9. Broggini M., Sommacampagna B., Paolini A., Dolfihi E. & Donelli M. S. (1986) Comparative metabolism of daunorubicin and 4-demethoxy-daunorubicin in mice and rabbits. Cancer Treat. Rep. 70, 697.
10. 10. Reid J. M., Pendergrass T. W., Krailo M. D., Hammond G. D. & Ames M. M. (1990) Plasma pharmacokinetics and cerebrospinal fluid concentrations of idarubicin and idarubicinol in pediatric leukemia patients: A children's cancer study group. Cancer Res. 50, 6525.
11. 11. Creutzig U., Ritter J., Zimmermann M. & Schellong G. (1993) Does cranial irradiation reduce the risk of bone marrow relapse in acute myelogenous leukemia? Unexpected results of the childhood acute myelogenous study BFM-87. J. Clin. Oncol. 11, 279.
12. 12. Sackmann-Muriel F., Fernandez Barbieri M. A., Santarelli M. T., Matus-Ridley M., Rosso A., Negri-Aranguren P., Cerutti Y., Gomel M. & Kvicala R. (1993) Results of treatment with an intensive combination induction regimen containing idarubicin in children with acute myeloblastic leukemia: Preliminary report of the Argentine Group for Treatment of Acute Leukemia. Semin. Oncol. 6(8), 34.
13. 13. Meeting Report (1988) Morphologic, immunologic and cytogenetic (MIC) working classification of the acute myeloid leukemias. Br. J. Haemat. 68, 487.
14. 14. Cheson B. D., Cassileth P. A., Head D. R., Schiffer C. A., Bennet J. M., Bloomfield C. D., Brunning R., Gale R. P., Grever M. R., Keating M. J., Sawitsky A., Staas S., Weinstein H. & Woods W. G. (1990) Report of the National Cancer Institute - Sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. J. Clin. Oncol. 8, 813.
15. 15. Creutzig U., Ritter J., Ludwig W. D., Harbott J., Loffler H. & Schellong G. (1993) Klassifikation der AML nasch morphologischen, immunologischen und zytogenetischen kriterien. Ubersicht unter berücksichtigung der subtypen in der Studie AML-BFM-87. Klin. Padiatr. 205, 272.
16. 16. Matutes E. & Catovsky D. (1994) The value of scoring systems for the diagnosis of biphenotypic leukemia and mature B-cell disorders. Leukemia, Lymphoma 13(1), 11.
17. 17. Rand J., Moloney W. & Sise H. (1969) Coagulation defects in acute promyelocytic leukemia. Arch. Intern. Med. 123, 39.
18. 18. Gralnick H. R. & Abrell E. (1973) Studies of procoagulant and fibrinolytic activity of promyelocytes in acute promyelocytic leukemia. Br. J. Haematol. 24, 89.
19. 19. Gralnick H. R. (1975) Acute promyelocytic leukemia: Haemorrhagic manifestation and morphologic criteria. Br. J. Haematol. 29, 373.
20. 20. Tallman M. & Kwaan H. C. (1992) Reassessing the hemostatic disorder associated with promyelocytic leukemia. Blood 79, 543.
21. 21. Dombret H., Sutton L., Duarte M., Daniel M. T., Leblond V., Castaigne S. & Degos L. (1992) Combined therapy with all-trans-retinoic acid and high-dose chemotherapy in patients with hyperleukocytic acute promyelocytic leukemia and severe visceral hemorrhage. Leukemia 6, 1237.
22. 22. Rodeghiero F. & Castaman G. (1994) The pathophysiology and treatment of hemorrhagic syndrome of acute promyelocytic leukemia. Leukemia 8(2), S20.
23. 23. Lemons R. S., Keller S., Gietzen D., Dufner J., Rebentisch M., Feusner J. & Eilender D. (1995) Acute promyelocytic leukemia. J. Pediatr. Hematol. Oncol. 17, 198.
24. 24. Kaplan E. L. & Meier P. (1958) Nonparametric estimation from incomplete observations. J. Amer. Stat. Assoc. 53, 457.
25. 25. Peto R., Pike M. C., Armitage P., Breslow E. N., Cox D. R., Howard S. V., Mantel N., McPherson J., Peto J. & Smith P. G. (1977) Design and analysis of randomized clinical trials requiring prolonged observation on each patient. II. Analysis and examples. Br. J. Cancer 35, 1.
26. 26. Tarone R. E. & Wara J. (1977) On distribution-free test for equality of survival distribution. Biometrika 64, 156.
27. 27. Iacuone J. J., Steinherz L. J. & Ablin A. R. (1993) Modifications for toxicity. Supportive care of children with cancer. In Current Therapy and Guidelines from the Children's Cancer Group (Ablin Arthur R., Ed.), p. 37. The Johns Hopkins University Press, Baltimore.
28. 28. Creutzig U., Ritter J. & Schellong G. for the AML-BFM Study Group (1990) Identification of two risk groups in Childhood Acute Myelogenous Leukemia after therapy intensification in study AML-BFM-83 as compared with study AML-BFM-78. Blood 75, 1932.
29. 29. Creutzig U., Ritter J., Zimmermann M., Bender-Götze C. & Scellong G. (1995) Seven-year survival exceeding 70% without bone-marrow transplantation in first remission in standard risk children with acute myelogenous leukemia. Results of studies AML-BFM-83 and 87. Blood 86, 1, 433a.
30. 30. Ritter J., Creutzig U. & Schellong G. (1992) Treatment results of three consecutive German childhood AML trials: BFM-78, 83, and 87. Leukemia 6, 2, 59.
31. 31. Creutzig U., Ritter J., Riehm H., Langermann H. J., Hewze G., Kabisch H., Stollmann B., Lassow U., Kaufmann U., Löffler H. & Schellong G. (1985) Improved treatment results in childhood acute myelogenous leukemia: a report of the German Cooperative Study AML-BFM-78. Blood 65, 298.
32. 32. Wiernik P. H. (1995) Idarubicin in induction therapy of AML. Ann. Hematol. 70, Suppl II, A99.
33. 33. Büchner T. L. (1995) State of the art and the contribution of idarubicin in acute myeloid leukemia. Ann. Hematol. 70, II, A100.
34. 34. Ritter J., Creutzig U. & Zimmermann M. for the cooperative childhood AML-BFM Study Group (1995) The specific role of idarubicin during induction therapy of childhood AML. Ann. Hematol. 70, II, A99.
35. 35. Arderlini P., Benjamin R. S., Wong F. C., Kantarjian H. M., Andreeff M., Kornblan S. M., O'Brien S., Mackay B., Ewer M. S., Pierce S. A. & Estey E. H. (1995) Idarubicin cardiotoxicity: a retrospective study in acute myeloid leukemia and myelodysplasia. J. Clin. Oncol. 13, 2827.
36. 36. Creutzig U., Ritter J., Budde M., Sutor A. & Schellong G. the German BFM Study Group (1987) Early deaths due to hemorrhage and leukostasis in childhood acute myelogenous leukemia. Cancer 60, 3071.
37. 37. Ravindranath Y., Abella E., Krischer J. P., Wiley J., Inoue S., Harris M., Chauvenet A., Alvarado C. S., Dubowy R., Ritchey A. K., Land V., Steuber C. P. & Weinstein H. (1992) Acute myeloid leukemia (AML) in Down's syndrome is highly responsive to chemotherapy: Experience on Pediatric Oncology Group AML Study 8498. Blood 80, 2210.
38. 38. Ravindranath Y., Abella E., Krischer J. P. & Weinstein H. for the Pediatric Oncology Group (POG) (1993) Acute myeloid leukemia (AML) in Down's syndrome: response and toxicity with high dose arabinoside cytosine. Proc. Am. Soc. Clin. Oncol. 12, 323.
39. 39. Kanamuru A., Yoshinobu T., Mitsune T., Murakami H., Asou N., Kobayashi T., Kuriyama K., Ohmoto E., Sakamaki H., Tsubaki K., Hiraoka A., Yamada O., Oh H., Saito K., Matsuda S., Minato K., Ueda T., Ohno R. & the Japan Adult Leukemia Study Group (1995) All-trans retinoic acid for the treatment of newly diagnosed acute promyelocytic leukemia. Blood 85, 1202.